ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
103 108,48
-0,98%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Aurinia Pharmaceuticals Inc (AUPH) Cours

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc (AUPH)

NASDAQ
8,01
0,27
(3,49%)
Fermé 18 Janvier 10:00PM
Retardé de 15 minutes
8,04
0,03
(0,37%)
Après les heures de négociation: 12:55AM
Retardé de 15 minutes

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Statistiques et détails clés

Dernier
8,04
Prix Achat
8,01
Prix Vente
8,40
Volume échangé
1 596 374
7,67 Fourchette du Jour 8,03
4,71 Plage de 52 semaines 10,67
Cap du marché
1,15B
Clôture Veille
7,74
Ouverture
7,81
Dernière Transaction
9
@
8.01
Dernière heure de transaction
Volume financier
US$ 12 542 976
VWAP
7,8572
Volume moyen (3 m)
1 441 471
Actions en circulation
142 990 974
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-14,68
Bénéfice par action (BPA)
-0,55
Chiffre d'affairess
175,51M
Bénéfice net
-78,02M

À propos de Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FS... Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.auriniapharma.com
Siège social
Victoria, British Columbia, Can
Fondé
-
Aurinia Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AUPH. Le dernier cours de clôture d'Aurinia Pharmaceuticals était de US$7,74. Au cours de la dernière année, les actions de Aurinia Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 4,71 à US$ 10,67.

Aurinia Pharmaceuticals compte actuellement 142 990 974 actions en circulation. La capitalisation boursière d'Aurinia Pharmaceuticals est de US$1,11 milliard. Aurinia Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -14.68.

Flux d'options Aurinia Pharmaceuticals (AUPH)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

231k

Calls / Puts

400,00%

Ach. / Vent.

66,67%

OTM / ITM

25,00%

Sweeps Ratio

0,00%

AUPH Dernières nouvelles

Plus de nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

25 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

25 Novembre 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

25 Novembre 2024
Edgar (US Regulatory)

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

New Guidelines Presented at ACR Convergence 2024 Recommend First-Line Therapy with LUPKYNIS® (voclosporin) as Part of a Triple Immunosuppressive LN Treatment Regimen Aurinia Pharmaceuticals Inc...

18 Novembre 2024
Business Wire

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR...

15 Novembre 2024
Business Wire

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 Novembre 2024
Edgar (US Regulatory)

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s management team will attend the Jefferies Healthcare Conference in London, November 19-21...

14 Novembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

13 Novembre 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

13 Novembre 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

07 Novembre 2024
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.12-1.470588235298.168.277.5217723777.79638569CS
4-0.96-10.666666666799.3057.5213587198.39420242CS
120.9914.04255319157.0510.676.99614414718.60147254CS
262.2939.82608695655.7510.675.19513431957.45656364CS
520.324.145077720217.7210.674.7115189366.59299876CS
156-10.8485-57.434417767418.888520.47524.0722309408.95118039CS
260-11.9-59.679037111319.9433.97154.07248241812.60871314CS

AUPH - Frequently Asked Questions (FAQ)

What is the current Aurinia Pharmaceuticals share price?
The current share price of Aurinia Pharmaceuticals is US$ 8,04
How many Aurinia Pharmaceuticals shares are in issue?
Aurinia Pharmaceuticals has 142 990 974 shares in issue
What is the market cap of Aurinia Pharmaceuticals?
The market capitalisation of Aurinia Pharmaceuticals is USD 1,11B
What is the 1 year trading range for Aurinia Pharmaceuticals share price?
Aurinia Pharmaceuticals has traded in the range of US$ 4,71 to US$ 10,67 during the past year
What is the PE ratio of Aurinia Pharmaceuticals?
The price to earnings ratio of Aurinia Pharmaceuticals is -14,68
What is the cash to sales ratio of Aurinia Pharmaceuticals?
The cash to sales ratio of Aurinia Pharmaceuticals is 6,53
What is the reporting currency for Aurinia Pharmaceuticals?
Aurinia Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Aurinia Pharmaceuticals?
The latest annual turnover of Aurinia Pharmaceuticals is USD 175,51M
What is the latest annual profit for Aurinia Pharmaceuticals?
The latest annual profit of Aurinia Pharmaceuticals is USD -78,02M
What is the registered address of Aurinia Pharmaceuticals?
The registered address for Aurinia Pharmaceuticals is 1203-4464 MARKHAM STREET, VICTORIA, BRITISH COLUMBIA, V8Z 7X8
What is the Aurinia Pharmaceuticals website address?
The website address for Aurinia Pharmaceuticals is www.auriniapharma.com
Which industry sector does Aurinia Pharmaceuticals operate in?
Aurinia Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
AUPH
Aurinia Pharmaceuticals
TG
A3LCK0
Raiffeisenlandesbank Nie...
BIT
F36481
Vontobel Financial Produ...
LSE
0NAG
Fair Value Reit
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés